EP0346830B1 — Use of opiate antagonists for the preparation of a pharmaceutical composition for the treatment of alcoholism
Assigned to Alko Oy AB · Expires 1995-05-10 · 31y expired
What this patent protects
Described is the use of opiate antagonists for the preparation of pharmaceutical compositions to be administered simultaneously or separately sequentially with alcohol in the treatment of alcoholism. These pharmaceutical compositions are capable of extinguishing the alcohol-drink…
USPTO Abstract
Described is the use of opiate antagonists for the preparation of pharmaceutical compositions to be administered simultaneously or separately sequentially with alcohol in the treatment of alcoholism. These pharmaceutical compositions are capable of extinguishing the alcohol-drinking response of alcoholics during a relatively short period of time by having the alcoholics drink alcoholic beverages repeatedly while the opiate antagonist contained in said pharmaceutical composition blocks the positive reinforcement effects of ethanol in the brain.
Drugs covered by this patent
- naloxone-hydrochloride (Naloxone Hydrochloride) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.